Intravenous Itraconazole (IV ITRA) for Prophylaxis (P) of Invasive Fungal Infections (IFI) in Patients (PTS) with Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

GLORIA N. MATTIUZZI1, E. ESTEY1, J. H. REX2, J. LIM1, S. PIERCE1, S. FADERL1, F. GILES1, D. THOMAS1, J. CORTES1, H. KANTARJIAN1

Author address: 

1M.D. Anderson Cancer Center. The University of Texas, Houston, TX, 2University of Texas Medical School, Houston, TX.

Abstract: 

Background: IFI is an important cause of morbidity in AML/MDS. We evaluated IV ITRA as P of IFI in this setting. Methods: 100 adults with newly diagnosed AML/MDS received 200 mg IVI BID for 2d, followed by 200 mg IV ITRA/day during initial induction chemotherapy. Results: 94/100 were evaluable with median age 65y. 73% had ANC
2001

abstract No: 

NULL

Full conference title: 

ICAAC 41st
    • ICAAC 41st